Day: February 14, 2022

TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQX:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that Premium Nickel Resources (“PNR”), a private Canadian company that provides direct exposure to nickel-copper-cobalt opportunities in the southern African region, has executed a definitive asset purchase agreement with the Liquidator of Tati Nickel Mining Company to acquire the Selkirk Mine and surrounding prospecting licenses and infrastructure in Botswana. ThreeD is a founding shareholder of PNR and currently owns approximately 9% of PNR’s total issued and outstanding common shares. Furthermore, Sheldon Inwentash, Chairman & CEO of ThreeD,...

VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and cryptocurrency technology company, is providing this default status report pursuant to National Policy 12-203 – Cease Trade Orders for Continuous Disclosure (“NP 12-203”). As announced in its press release dated January 28, 2020, the Company’s principal securities regulator, the British Columbia Securities Commission, granted a management cease trade order (the “MCTO”) effective as of January 31, 2022 under NP 12-203. As disclosed in the Company’s press release dated January 26, 2022, the Company was advised by its external auditors (the “Auditors”) that they will require additional time to complete its internal review and audit...

– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evaluating bavdegalutamide in patients with mCRPC who have progressed on or after novel hormonal agents (NHAs) and have tumors that harbor AR T878X/H875Y mutations – – Updated data to be presented in a rapid abstract session and a poster session at ASCO GU and Arvinas to hold conference call on Thursday, February 17 at 8:30 a.m. ET – NEW HAVEN, Conn., Feb. 14, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the presentation of new data showing that bavdegalutamide (also...

PLANO, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) — Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions provider for U.S. banks and credit unions, today announced that it plans to report financial results for its fourth quarter ended December 31, 2021 on Wednesday, February 23, 2022, after the market close. The Company will host a conference call at 5:00 p.m. ET the same day to discuss its financial results with investors. A live webcast of the event will be available on the “News & Events” page of the Alkami investor relations website at investors.alkami.com. In addition, a live dial-in will be available domestically at 1 (800) 708-4540 and internationally at 1 (847) 619-6397, using passcode 50279506. The webcast replay will be available on the Alkami investor relations website. About...

PLAINVIEW, NY, Feb. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Italian Food & Beverage Corp. (OTC- IFBC). Dino Luzzi Energy Drink racing team has started in collaboration with Alan Cohen! Partnering with Nasa Racing and with our Energy drink logo on his mustang viewed livestream on YouTube https://rb.gy/fwddnp in the Nasa Nationals in Daytona, in that race Alan Cohen became Super Unlimited Champion for the Nasa NE Region. Having the race live with our logo on the race car brought many spectators- drivers and mechanics to visit our booth to taste our energy drink and the feedback was incredibly positive. This year the No. 45 Dino Luzzi Mustang started its journey at the U.S. Majors Tour events and the SCCA National Championship Runoffs at VIR, we will be on site at select Hoosier Super Tour and Enduro National Tour events...

SAN CLEMENTE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Concierge Technologies, Inc. (OTC Pink: CNCG), a diversified global holding firm, today reported financial results for the second fiscal quarter and six months ended December 31, 2021. Revenues for the second fiscal quarter totaled $9,445,116, compared with $9,961,822 a year ago. Net income for the most recent three-month period was $1,023,335, equal to $0.03 per fully diluted per share, compared with $1,351,788, or $0.04 per fully diluted share, last year. “Each of our operating subsidiaries posted income from operations for the second fiscal quarter as they continued to pursue growth opportunities through new products and sales channel expansion,” said David Neibert, Concierge Technologies’ Chief Operations Officer. “At the top level, we continued our investment...

MONDOVI, Wis., Feb. 14, 2022 (GLOBE NEWSWIRE) — Marten Transport, Ltd. (Nasdaq/GS:MRTN) today announced its dry truckload operations have begun hauling dry van products between Mexico and the U.S. with the first load delivering on time, as expected, February 11th. This added dry van transportation service solution for Marten’s customers will enhance the already strong profitable growth of both Marten’s dry regional truckload operations and MRTN de Mexico’s refrigerated operations. With these additional services, Marten is broadening its dry truckload operations from the Company’s terminal facilities in Atlanta, Kansas City, Tampa and Phoenix into its Dallas, Laredo, and Otay Mesa facilities.         Dry Regional Truckload Profitable Growth                   Percentage   Percentage   Percentage          Increase   Increase   Increase          Year   Year   Year          Ended   Ended   Ended          December...

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA® (tivozanib) Data Presented at the ASCO 2022 GU Cancers Symposium BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) — AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new long-term progression free survival (PFS) data from the Phase 3 TIVO-3 study, which compares FOTIVDA® (tivozanib) to Nexavar® (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies, are being presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers...